Therapeutic drug monitoring for optimizing amisulpride therapy in patients with Schizophrenia

Journal of Psychiatric Research

Volumn 41, Issue 8, 2007, Pages 673-679

  Müller, Matthias J ^a   Regenbogen, Boris ^a   Härtter, Sebastian ^a   Eich, Franz X ^b   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Sanofi Aventis Dt GmbH   (Germany)

Author keywords

Amisulpride; Schizophrenia; Therapeutic drug monitoring

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LITHIUM; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; BLURRED VISION; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSALIVATION; HYPOSALIVATION; MAJOR CLINICAL STUDY; MALE; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DYSKINESIA, DRUG-INDUCED; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; ROC CURVE; SCHIZOPHRENIA; STATISTICS; SULPIRIDE;

EID: 33947681636     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2005.10.003     Document Type: Article

References (40)

1. Awad A.G., and Voruganti L.N. New antipsychotics, compliance, quality of life, and subjective tolerability - are patients better off?. Canadian Journal of Psychiatry 49 (2004) 297-302
2. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., Kuss H.J., Laux G., Müller-Oerlinghausen B., Rao M.L., Riederer P., and Zernig G. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37 (2004) 243-265
3. Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau". Therapeutic Drug Monitoring 26 (2004) 145-151
4. Bergemann N., Kopitz J., Kress K.R., and Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. European Neuropsychopharmacology 14 (2004) 245-250
5. Brøsen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Therapeutic Drug Monitoring 18 (1996) 393-396
6. Cook R.J., and Sackett D.L. The number needed to treat: a clinically useful measure of treatment effect. British Medical Journal 310 (1995) 452-454
7. Correll C.U., Leucht S., and Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. American Journal of Psychiatry 161 (2004) 414-425
8. Coulouvrat C., and Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. International Clinical Psychopharmacology 14 (1999) 209-218
9. Eilers R. Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness. Clinical Pharmacokinetics 29 (1995) 442-450
10. Fitzgerald P.B., Kapur S., Remington G., Roy P., and Zipursky R.B. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berlin) 149 (2000) 1-5
11. Gardner D.M., and Hardy B.G. Cost-effectiveness of therapeutic drug monitoring. Canadian Journal of Hospital Pharmacy 43 (1990) 7-12
12. Gründer G., and Wong D.F. The next generation of "atypical" antipsychotics: the role of positron emission tomography. Fortschritte Neurologie Psychiatrie 71 (2003) 415-420
13. In: Guy D. (Ed). ECDEU Assessment Manual for Psychopharmacology. revised ed. (1976), NIMH, DHEU Publication, Rockville
14. Hanley J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29-36
15. Hiemke C., Dragicevic A., Gründer G., Härtter S., Sachse J., Vernaleken I., and Müller M.J. Therapeutic monitoring of new antipsychotic drugs. Therapeutic Drug Monitoring 26 (2004) 156-160
16. Kapur S., Arenovich T., Agid O., Zipursky R., Lindborg S., and Jones B. Evidence for onset of antipsychotic effects within the first 24 h of treatment. American Journal of Psychiatry 162 (2005) 939-946
17. Kasper S., Tauscher J., Küfferle B., Barnas C., Pezawas L., and Quiner S. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. European Archives of Psychiatry and Clinical Neurosciences 249 Suppl. 4 (1999) 83-89
18. Lecrubier Y. Amisulpride: progress and outcomes. Current Medical Research and Opinion 18 Suppl. 3 (2002) 18-22
19. Leslie D.L., and Rosenheck R.A. Adherence of schizophrenia pharmacotherapy to published treatment recommendations: patient, facility, and provider predictors. Schizophrenia Bulletin 30 (2004) 649-658
20. Leucht S., Busch R., Hamann J., Kissling W., and Kane J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological Psychiatry 57 (2005) 1543-1549
21. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica 334 (1987) 1-100
22. McKeage K., and Plosker G.L. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 18 (2004) 933-956
23. MedCalc Software. MedCalc Computer program, Version 7.6.0.0 (2005), Frank Schoonjans, Mariakerke, Belgium
24. Möller H.J. Amisulpride: a review of its efficacy in schizophrenia. Acta Psychiatrica Scandinavica Supplement 400 (2000) 17-22
25. Mortimer A., Martin S., Loo H., and Peuskens J. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. International Clinical Psychopharmacology 19 (2004) 63-69
26. Mota N.E., Lima M.S., and Soares B.G. Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews 2 (2002) CD001357
27. Müller M.J., and Benkert O. Der Stellenwert von Amisulprid in der Behandlung von Patienten mit schizophrenen Erkrankungen - Ergebnisse kontrollierter Studien. In: Hippius H. (Ed). Amisulprid (2002), Urban und Vogel, München 33-57
28. Preskorn S.H., Dorey R.C., and Jerkovich G.S. Therapeutic drug monitoring of tricyclic antidepressants. Clinical Chemistry 34 (1988) 822-828
29. Rein W., Coulouvrat C., and Dondey-Nouvel L. Safety profile of amisulpride in short- and long-term use. Acta Psychiatrica Scandinavica Supplement 400 (2000) 23-27
30. Rettenbacher M.A., Hofer A., Eder U., Hummer M., Kemmler G., Weiss E.M., and Fleischhacker W.W. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. Journal of Clinical Psychiatry 65 (2004) 1211-1218
31. Sachse J., Härtter S., Weigmann H., and Hiemke C. Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. Journal of Chromatography B 784 (2003) 405-410
32. Sinclair J.C., and Bracken M.B. Clinically useful measures of effect in binary analyses of randomized trials. Journal of Clinical Epidemiology 47 (1994) 881-889
33. Spina E., D'Arrigo C., Migliardi G., Morgante L., Zoccali R., Ancione M., and Madia A.. Plasma risperidone concentrations during combined treatment with sertraline. Therapeutic Drug Monitoring 26 (2004) 386-390
34. Touw D.J., Neef C., Thomson A.H., and Vinks A.A. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Therapeutic Drug Monitoring 27 (2005) 10-17
35. Valenstein M., Blow F.C., Copeland L.A., McCarthy J.F., Zeber J.E., Gillon L., Bingham C.R., and Stavenger T. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bulletin 30 (2004) 255-264
36. Vernaleken I., Siessmeier T., Buchholz H.G., Härtter S., Hiemke C., Stoeter P., Rösch F., Bartenstein P., and Gründer G. High striatal occupancy of D2-like dopamine receptors by amisulpride in brain of patients with schizophrenia. International Journal of Neuropsychopharmacology 7 (2004) 421-430
37. Weiden P.J., Kozma C., Grogg A., and Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatry Services 55 (2004) 886-891
38. Xiberas X., Martinot J.L., Mallet L., Artiges E., Canal M., Loc'h C., Maziere B., and Paillere-Martinot M.L. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. Journal of Clinical Psychopharmacology 21 (2001) 207-214
39. Xiberas X., Martinot J.L., Mallet L., Artiges E., Loc'H C., Maziere B., and Paillere-Martinot M.L. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. British Journal of Psychiatry 179 (2001) 503-508
40. Zweig M.H., and Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clinical Chemistry 39 (1993) 561-577